Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Current Liabilities (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Total Current Liabilities data on record, last reported at $53.4 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 28.21% year-over-year to $53.4 million; the TTM value through Sep 2025 reached $53.4 million, up 28.21%, while the annual FY2024 figure was $47.8 million, 21.87% up from the prior year.
  • Total Current Liabilities reached $53.4 million in Q3 2025 per ASMB's latest filing, up from $47.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $53.4 million in Q3 2025 and bottomed at $7.1 million in Q3 2023.
  • Average Total Current Liabilities over 5 years is $26.3 million, with a median of $16.1 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: crashed 53.87% in 2023, then surged 483.78% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $16.1 million in 2021, then grew by 1.39% to $16.3 million in 2022, then skyrocketed by 140.7% to $39.2 million in 2023, then grew by 21.87% to $47.8 million in 2024, then rose by 11.67% to $53.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $53.4 million in Q3 2025, $47.3 million in Q2 2025, and $46.6 million in Q1 2025.